KQB365

KQB365 is an investigational anti-cancer drug developed by Kumquat Biosciences. It is currently being evaluated in a Phase 1/1b open-label, multicenter clinical trial for the treatment of advanced solid malignancies, particularly those harboring KRAS G12C or G12S mutations. The study includes both monotherapy and combination therapy arms (with cetuximab). The primary objectives are to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in adults with unresectable or metastatic disease who have no available curative treatment options. While the precise mechanism of action has not been publicly disclosed as of June 2025, the drug is being targeted at cancers with specific KRAS mutations—a well-known oncogenic driver in several tumor types including colorectal cancer[3][4][5][6].